|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 34-year-old nulliparous woman at 5 weeks of gestation was diagnosed with estrogen receptor (ER) positive, progesterone receptor (PR) positive and human epidermal growth factor receptor-2 (HER-2) negative infiltrating intraductal carcinoma.
|
30403906 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, we discuss emerging experimental models of ER+/PR+ DCIS.
|
30338425 |
2018 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of ER, PR were significantly higher in DCIS compared with DCIS with microinvasion (P < .001, P < .001).
|
30383678 |
2018 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We retrospectively examined paraffin-embedded biopsy specimens of BC (n = 62), ductal carcinoma in situ (n = 19), and adjacent normal breast tissue (n = 42) for HCMV immediate-early protein (IE), HCMV late antigen, HCMV DNA and RNA, and investigated possible correlations between them and expression of ER-α, PgR, and HER2.
|
28595965 |
2017 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to identify the gene-expression signature profiles of estrogen receptor (ER)/progesterone receptor (PR)-positive, ERBB2, and triple-negative subtypes of DCIS.
|
28178722 |
2017 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the subset of invasive breast cancer cases with adjacent ductal carcinoma in situ (n=83), a complete concordance was observed between the estrogen receptor, progesterone receptor, and HER2 status of both components.
|
28084333 |
2017 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of patient DCIS revealed a significant correlation between high nuclear BCL9 and pathologic characteristics associated with DCIS recurrence: Estrogen receptor (ER) and progesterone receptor (PR) negative, high nuclear grade, and high human epidermal growth factor receptor2 (HER2).
|
26384318 |
2015 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A low score was not observed in any case with at least two of the following--negative PR, >1 mitotic figure, and/or presence of dense chronic inflammation around ductal carcinoma in situ (100% specificity).
|
26111975 |
2015 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ER (n=112), PR (n=113) and HER2 (n=114) status from both the primary DCIS and the corresponding relapse were assessed and were demonstrated to be discordant in 15.1%, 29.2% and 10.5% respectively.
|
24275214 |
2014 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GATA4 status was significantly associated with nuclear grade and van Nuys classification in DCIS and was positively associated with distant metastasis, histological grade and HER2 status, but negatively correlated with progesterone receptor labeling index in IDC.
|
24862985 |
2014 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In both DCIS and IDC, a significant positive correlation was observed between ER and PgR receptor expression (r = 0.67, P = 0.00; r = 0.56, P = 0.00, respectively).
|
19657752 |
2010 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of estrogen receptor (ER), progesterone receptor (PR), HER2, HER4, and cystatin M was retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (DCIS) and in 175 patients with invasive breast cancer (IBC).
|
21092257 |
2010 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERalpha and PR expression decreased from 62% in ductal carcinoma in situ (DCIS) to 20% and 16% in pT3, respectively (p value for ER 0.025 and PR 0.035, Fisher's exact test).
|
19381686 |
2009 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the significance of these mechanisms on an early stage of human breast tumour growth, we studied the expression of EGFR (ErbB1), HER-2/neu (ErbB2), cyclin D1, p21 and p53 as well as oestrogen (ER) and progesterone receptor (PgR) in paraffin sections of 45 ductal carcinoma in situ (DCIS) by immunohistochemistry.
|
12825853 |
2003 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DCIS and IDC cases with a stem cell phenotype were ER/PgR negative and intermediately or poorly differentiated.
|
12037031 |
2002 |
|
Noninfiltrating Intraductal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used quantitative immunohistochemical analysis for the oestrogen receptor (ER), progesterone receptor (PgR), cyclin D1 and pS2 on sections of primary tumours and ductal carcinoma in situ (DCIS).
|
9893652 |
1998 |